GH Research Reports Full Year 2023 Financial Results and Provides Business Updates
February 29, 2024 07:00 ET
|
GH Research PLC
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024Phase 2a clinical trial of GH001 in postpartum...
GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression
January 18, 2024 16:30 ET
|
GH Research PLC
DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports Third Quarter Financial Results and Provides Business Updates
November 09, 2023 16:45 ET
|
GH Research PLC
DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
September 29, 2023 16:45 ET
|
GH Research PLC
DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 23, 2023 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights
May 11, 2023 07:30 ET
|
GH Research PLC
DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
March 02, 2023 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Provides Business Updates and Highlights Key Upcoming Milestones
January 09, 2023 07:30 ET
|
GH Research PLC
Initial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023Development of proprietary aerosol delivery device for GH001 progressed, IND...
GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 10, 2022 07:05 ET
|
GH Research PLC
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
August 23, 2022 07:00 ET
|
GH Research PLC
DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...